Samenvatting
BBS3012: Summary of all cases and Lectures
- Instelling
- Maastricht University (UM)
All cases and lectures from the course BBS3012 from the minor Drug Intervention Track
[Meer zien]Voorbeeld 4 van de 118 pagina's
Voorbeeld 4 van de 118 pagina's
In winkelwagengesponsord bericht van onze partner
Voorbeeld van de inhoud
BBS3012: FROM PHARMACOLOGICALMECHANISMS TO PRECISION MEDICINE
All cases and lectures
Biomedical Sciences: Minor Drug Intervention Track
1
,INHOUDSOPGAVE
Case 1: pharmacodynamics ............................................................................................................................ 5
Katzung, B. (2018). Basic & clinical pharmacology Chapter 2: Drug Receptors & Pharmacodynamics ............ 12
MACROMOLECULAR NATURE OF DRUG RECEPTORS ................................................................................... 12
(Case 2) ........................................................................................................................................................ 25
Case 3 .......................................................................................................................................................... 26
How is alcohol metabolized? ............................................................................................................................ 26
Interference (pharmacokinetics, pharmacodynamics) ................................................................................. 27
Estimate Peters’ blood alcohol level? ........................................................................................................... 27
ADME of paracetamol....................................................................................................................................... 28
WHat is the mechanism behind paracetamol toxicity? .................................................................................... 28
How can you treat this toxicity (NAC, gastric lavage)? ................................................................................. 30
Case 4: phenytoin interactions ..................................................................................................................... 32
What is phenytoin? Mode of action? Pharmacokinetic profile? ....................................................................... 32
Mechanism of action .................................................................................................................................... 32
Pharmacokinetic profile ................................................................................................................................ 32
What is plasma protein binding? What proteins are involved? ........................................................................ 33
What is the effect on the pharmaco-dynamics and -kinetics of the compounds? ............................................ 34
Explain the case (displacement of plasma proteins à how?, consequences?)................................................. 34
Would reduction of the dose solve this problem? If so, how?........................................................................... 35
Case 5: drug-drug interactions ...................................................................................................................... 36
Drug-drug interactions...................................................................................................................................... 36
Chapter 4, Drug-drug interactions ................................................................................................................ 36
Pharmacodynamic interactions .................................................................................................................... 37
Pharmacokinetic interactions ....................................................................................................................... 38
Mode of action of the mentioned drugs, pd, Toxic effects, concentrations and dose, PK, possible interactions?
.......................................................................................................................................................................... 40
Colchicine ...................................................................................................................................................... 40
Cyclosporine.................................................................................................................................................. 41
Mycophenolate mofetil ................................................................................................................................ 43
Prednisone .................................................................................................................................................... 44
Simvastatin ................................................................................................................................................... 46
Propofol ........................................................................................................................................................ 47
What is rhabdomyolysis? Drug-related causes? ............................................................................................... 49
Case 6 .......................................................................................................................................................... 52
PK and PD of codeine ........................................................................................................................................ 52
Impact of polymorphisms of CYP enzymes, prevalence of polymorphisms ....................................................... 53
What are CYP450 enzymes? Nomenclature? role in metabolism? ................................................................... 53
Genetic Polymorphism and Toxicology—With Emphasis on Cytochrome P450 Inger Johansson, Magnus
Ingelman-Sundberg....................................................................................................................................... 56
Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects
and functional diversity M Ingelman-Sundberg............................................................................................ 58
How do diet and other drugs interact with codeine? ........................................................................................ 58
2
, Information on opioids in general ..................................................................................................................... 58
Case 7 .......................................................................................................................................................... 60
What are the effects of age on drug response? ................................................................................................ 60
PK (body composition, metabolism) ............................................................................................................. 60
PD (sensitivity) .............................................................................................................................................. 61
What is the mode of action of sulphidimidine and chloramphenicol? .............................................................. 62
Sulphadimidine (Sulfamethazine) ................................................................................................................. 62
Chloramphenicol ........................................................................................................................................... 62
Ampicillin ...................................................................................................................................................... 63
What is the mode of action of methotrexate? .................................................................................................. 63
Side-effects (incl. nausea) ............................................................................................................................. 63
Interaction with folic acid ............................................................................................................................. 64
Case 8 .......................................................................................................................................................... 66
Lungcancer ........................................................................................................................................................ 66
Pathophysiology............................................................................................................................................ 66
types and stages ........................................................................................................................................... 67
What are EGFR and ALK? .................................................................................................................................. 69
How does screening help in choosing cancer treatment? ............................................................................ 69
What is a panel test? What panels are there? .................................................................................................. 69
What is RET? ................................................................................................................................................. 70
What is Alectinib? Why is it used in this case?.................................................................................................. 70
What is germline genetic screening? What is it used for? ................................................................................ 71
What kind of genes do you have to screen in order to predict efficacy and toxicity of drugs? ......................... 72
Look at results of genetic toxicity practical ....................................................................................................... 73
Lecture: pharmacodynamics 2 M. Blankesteijn ............................................................................................. 74
Lecture: pharmacokinetics 1 G. den Hartog .................................................................................................. 80
Quantifying events following an intravenous bolus .......................................................................................... 86
Volume of distribution and clearance........................................................................................................... 87
Quantifying Events Following an Oral Dose ...................................................................................................... 89
Lecture pharmacokinetics 2 G. den Hartog ................................................................................................... 91
Renal excretion ................................................................................................................................................. 91
Enzyme induction .............................................................................................................................................. 93
Multiple dosing ................................................................................................................................................. 95
Lecture: question hour ................................................................................................................................. 98
Lecture: pharmacoepigenetics A. Weseler .................................................................................................. 100
DNA modification: (de)methylation ................................................................................................................ 100
Histone modifications ..................................................................................................................................... 101
Non-coding (nc)-RNA’s .................................................................................................................................... 101
ADME genes .................................................................................................................................................... 101
Epigenetic effects of drugs .............................................................................................................................. 102
3
, Pharmaco-epigenetics à precision medicine ................................................................................................. 103
Take home messages ...................................................................................................................................... 104
Lecture: pharmacotherapy from cradle to grave A. Weseler ....................................................................... 105
What to take into account for the pharmacotherapy of patients of different age? ....................................... 108
Lecture: Gut microbiome and drug response D. Jonkers ............................................................................. 113
4
Voordelen van het kopen van samenvattingen bij Stuvia op een rij:
Verzekerd van kwaliteit door reviews
Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!
Snel en makkelijk kopen
Je betaalt supersnel en eenmalig met iDeal, creditcard of Stuvia-tegoed voor de samenvatting. Zonder lidmaatschap.
Focus op de essentie
Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!
Veelgestelde vragen
Wat krijg ik als ik dit document koop?
Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.
Tevredenheidsgarantie: hoe werkt dat?
Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.
Van wie koop ik deze samenvatting?
Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper ashleymaes. Stuvia faciliteert de betaling aan de verkoper.
Zit ik meteen vast aan een abonnement?
Nee, je koopt alleen deze samenvatting voor €11,49. Je zit daarna nergens aan vast.
Is Stuvia te vertrouwen?
4,6 sterren op Google & Trustpilot (+1000 reviews)
Afgelopen 30 dagen zijn er 72042 samenvattingen verkocht
Opgericht in 2010, al 14 jaar dé plek om samenvattingen te kopen